These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
920 related articles for article (PubMed ID: 12015757)
1. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757 [TBL] [Abstract][Full Text] [Related]
2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907 [TBL] [Abstract][Full Text] [Related]
5. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198 [TBL] [Abstract][Full Text] [Related]
6. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067 [TBL] [Abstract][Full Text] [Related]
7. Adrenocortical carcinoma. van Ditzhuijsen CI; van de Weijer R; Haak HR Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxic chemotherapy for adrenocortical carcinoma. Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727 [TBL] [Abstract][Full Text] [Related]
10. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Feller N; Hoekman K; Kuiper CM; Linn SC; Verheul HM; Wolthers BG; Popp-Snijders C; Pinedo HM Clin Cancer Res; 1997 Mar; 3(3):389-94. PubMed ID: 9815696 [TBL] [Abstract][Full Text] [Related]
11. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647 [TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
14. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Yoh K; Goto K; Ishii G; Niho S; Ohmatsu H; Kubota K; Kakinuma R; Nagai K; Suga M; Nishiwaki Y Cancer; 2003 Sep; 98(5):926-31. PubMed ID: 12942558 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028 [TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105 [TBL] [Abstract][Full Text] [Related]
18. Mitotane treatment for adrenocortical carcinoma: an overview. De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612 [TBL] [Abstract][Full Text] [Related]
19. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]